Terms: = Lymphoma AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Staging
12 results:
1. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.
Kemps PG; Hebeda KM; Pals ST; Verdijk RM; Lam KH; Bruggink AH; de Lil HS; Ruiterkamp B; de Heer K; van Laar JA; Valk PJ; Mutsaers P; Levin MD; Hogendoorn PC; van Halteren AG
J Pathol Clin Res; 2021 Jan; 7(1):10-26. PubMed ID: 32852896
[TBL] [Abstract] [Full Text] [Related]
2. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Kerr KM; Dafni U; Schulze K; Thunnissen E; Bubendorf L; Hager H; Finn S; Biernat W; Vliegen L; Losa JH; Marchetti A; Cheney R; Warth A; Speel EJ; Blackhall F; Monkhorst K; Jantus Lewintre E; Tischler V; Clark C; Bertran-Alamillo J; Meldgaard P; Gately K; Wrona A; Vandenberghe P; Felip E; De Luca G; Savic S; Muley T; Smit EF; Dingemans AC; Priest L; Baas P; Camps C; Weder W; Polydoropoulou V; Geiger TR; Kammler R; Sumiyoshi T; Molina MA; Shames DS; Stahel RA; Peters S;
Ann Oncol; 2018 Jan; 29(1):200-208. PubMed ID: 29186353
[TBL] [Abstract] [Full Text] [Related]
3. [Association between the ALK Gene Status and the Efficacy of First-line
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001
[TBL] [Abstract] [Full Text] [Related]
4. Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.
Rusthoven CG; Doebele RC
J Clin Oncol; 2016 Aug; 34(24):2814-9. PubMed ID: 27298405
[TBL] [Abstract] [Full Text] [Related]
5. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Schneider F; Derrick V; Davison JM; Strollo D; Incharoen P; Dacic S
Mod Pathol; 2016 Jul; 29(7):735-42. PubMed ID: 27080983
[TBL] [Abstract] [Full Text] [Related]
6. An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung.
Zenali MJ; Weissferdt A; Solis LM; Ali S; Tang X; Mehran RJ; Wistuba II; Moran CA; Kalhor N
Hum Pathol; 2015 Jun; 46(6):836-42. PubMed ID: 25776025
[TBL] [Abstract] [Full Text] [Related]
7. Molecular testing and personalized treatment of lung cancer.
Sampsonas F; Ryan D; McPhillips D; Breen DP
Curr Mol Pharmacol; 2014; 7(1):22-32. PubMed ID: 25563851
[TBL] [Abstract] [Full Text] [Related]
8. Learning curve for endobronchial ultrasound‑guided transbronchial needle aspiration: experience of a community‑based teaching hospital.
Wang H; D'Cruz C; Yam DC; Dilla LM; Tsang P
Mol Med Rep; 2014 Nov; 10(5):2441-6. PubMed ID: 25189939
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic and predictive biomarkers in lung cancer. A review.
Thunnissen E; van der Oord K; den Bakker M
Virchows Arch; 2014 Mar; 464(3):347-58. PubMed ID: 24420742
[TBL] [Abstract] [Full Text] [Related]
10. The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma.
Jurado J; Saqi A; Maxfield R; Newmark A; Lavelle M; Bacchetta M; Gorenstein L; Dovidio F; Ginsburg ME; Sonett J; Bulman W
Ann Thorac Surg; 2013 Oct; 96(4):1196-1202. PubMed ID: 23972930
[TBL] [Abstract] [Full Text] [Related]
11. How I do it--optimal methodology for multidirectional analysis of endobronchial ultrasound-guided transbronchial needle aspiration samples.
Nakajima T; Yasufuku K
J Thorac Oncol; 2011 Jan; 6(1):203-6. PubMed ID: 21178716
[TBL] [Abstract] [Full Text] [Related]
12. [Current options and principles of pathomorphology-based tumour diagnostics].
Povýsil C
Vnitr Lek; 2010 Jul; 56(7):709-14. PubMed ID: 20842917
[TBL] [Abstract] [Full Text] [Related]
